The rise of Sildenafil initially sparked a surge for pharma, nevertheless recent developments present a complicated outlook for investors. Off-patent competitors are reducing revenue, and ongoing patent challenges add https://joycenxfs711697.iyublog.com/39962522/viagra-and-big-pharma-a-volatile-investment